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Background: Data accuracy and completeness are crucial for ensuring both the correctness and epidemiological
relevance of a given data set. In this study we evaluated a clinical register in the administrative district of Marburg-
Biedenkopf, Germany, for these criteria.
Methods: The register contained data gathered from a comprehensive integrated breast-cancer network from
three hospitals that treated all included incident cases of malignant breast cancer in two distinct time periods from
1996–97 (N=389) and 2003–04 (N=488). To assess the accuracy of this data, we compared distributions of risk,
prognostic, and predictive factors with distributions from established secondary databases to detect any deviations
from these “true” population parameters. To evaluate data completeness, we calculated epidemiological standard
measures as well as incidence-mortality-ratios (IMRs).
Results: In total, 12% (13 of 109) of the variables exhibited inaccuracies: 9% (5 out of 56) in 1996–97 and 15% (8 out of
53) in 2003–04. In contrast to raw, unstandardized incidence rates, (in-) directly age-standardized incidence rates
showed no systematic deviations. Our final completeness estimates were IMR=36% (1996–97) and IMR=43% (2003–04).
Conclusion: Overall, the register contained accurate, complete, and correct data. Regional differences accounted for
detected inaccuracies. Demographic shifts occurred. Age-standardized measures indicate an acceptable degree of
completeness. The IMR method of measuring completeness was inappropriate for incidence-based data registers. For
the rising number of population-based health-care networks, further methodological advancements are necessary.
Correct and epidemiologically relevant data are crucial for clinical and health-policy decision-making.
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Today0s information technologies make it possible to
collect and process comprehensive population-based
public-health data. Cohort studies and data register col-
lect, check, and analyze medical data in regular time
intervals. This procedure is intended to provide high-
quality data on which crucial health-policy decisions can* Correspondence: christian.jacke@zi-mannheim.de
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reproduction in any medium, provided the orbe based. The goal of this so-called “public-disclosure
strategy” is to increase health care system transparency
of and for all stakeholders related to public health [1,2].
Increased transparency is important for various stake-
holders (patients, physicians, hospital management,
health insurers, clinical-trial coordinators, policymakers,
etc.) in different settings (primary care, in-home care,
biodatabases, etc.) and on various levels (micro, meso
and macro) with regard to aspects of health care quality
(structures, processes, outcomes) [3,4]. In all of the cases
above, it is the quality of the data, as well as itstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the subsequent information and decisions. Thus, deci-
sions can never be better than the information retrieved
from the data they are based on.
The common conception of data quality
But what does “data quality” really mean? The scientific
community has established standards such as objectivity,
reliability, and validity of measurement instruments to
ensure reproducible and comparable research results [5-7].
There have been, for example, various exploratory
data-analysis methodologies in common use, each
offering an independent method for achieving these
standards [8,9]. In an effort to standardize these vari-
ous methods, cancer registers have published extensive
manuals of these numerous methods [10] to improve
the validity of the comparable epidemiological indices
used for health-monitoring reports. However, these
manuals do not make theoretical distinctions between
levels of data quality and they do not offer an integra-
tive framework for explorative methods. To overcome
these shortcomings the “GUIDELINES FOR THE
ADAPTIVE MANAGEMENT OF DATA QUALITY
FOR COHORT STUDIES AND REGISTERS” (GAMOQ)
[6,7,11] were developed.
The level-based conception of data quality
These GAMOQ were developed in 2006 by the technology
and methodology platform for networked medical research
(TMF) to facilitate the independent assessment of data
quality as well as its subsequent improvement. An exten-
sive literature review and expert interviews were part of
the development process [7]. The GAMOQ differentiated
the term “data quality” into three distinct levels – data
plausibility, data organization, and data correctness – cor-
responding to the already-existing assessment approaches
for quality of medical care (structure, process, and out-
come quality) [4,12]. Each of these data levels encompasses
specific data-quality indicators (DQIs). In total there are 24
DQIs which assess different aspects of a data set or regis-
ter. A general proof of feasibility, usefulness, and practic-
ability of this methodological framework has already been
reported elsewhere [13,14].
Data accuracy and completeness as objectives
Here we aim to present the most important results con-
cerning data-level correctness of a population-based
clinical breast-cancer registry from the longitudinal
point of view. Of particular interest are the DQIs accur-
acy and completeness, both of which allow classifying a
data set0s epidemiological relevance. In the following, ac-
curacy refers to the degree to which the primary data
differ from the population0s “true” parameters deter-
mined by using established secondary data sources [7].Completeness refers to the degree to which the primary
data have captured all relevant patients in accordance
with the inclusion criteria [7]. The leading hypothesis
assumes that the current population-based breast-cancer




The primary data to be assessed was collected in three hos-
pitals in the administrative district of Marburg-Biedenkopf,
Germany. They included all females that were treated in
these hospitals for the first time for malignant breast can-
cer (ICD-10: C.50). Recruiting was carried out within the
context of two prospective cohort studies that took place
in the periods from 1996–97 and 2003–04. The population
surveys were conducted independently of one another, and
thus the data was not processed according to a uniform
standard. It was saved in different file formats (Excel,
SPSS). In total, 1,389 (1996–97) and 150 variables
(2003–04) related to demographic, socioeconomic, and
medical issues were collected. The variable names and
value codes of the two data sets0 variables were synchro-
nized. The data sets were transferred to a clinical register
called the Breast Cancer Query Database (BCQDB). The
accuracy and completeness of the BCQDB was assessed.
The study was approved and conducted according to the
guidelines of the local ethics committee of the Philipps
University Marburg (Germany).
Secondary databases
Additional secondary data sources with high data-quality
standards were used to estimate the epidemiological accur-
acy and completeness of the BCQDB. The “National Field
Study for the Assessment of the Quality of Breast Cancer
Care” [15] provided distributions and parameter estimates
for risk, prognostic, and predictive factors for breast cancer,
as did the common cancer registers of the German federal
states of Berlin, Brandenburg, Mecklenburg-Vorpommern,
Saxony-Anhalt, Saxony, and Thuringia [16,17], as well as
the Munich Tumor Register [18]. For comparison pur-
poses, we also integrated raw and age standardized inci-
dence rates from the epidemiological cancer register of
Saarland, Germany, and the German Center for Cancer
Registry Data located at the Robert Koch Institute (RKI).
To estimate mortality-incidence ratios, we integrated
breast-cancer-specific mortality rates kept by the regional
statistic authorities of the German federal state of Hesse.
Measures of data accuracy
The central idea of the GAMOQ is to assess data qual-
ity, if necessary by source data verification techniques,
by comparing the dataset for a cohort study or a data
register (in this case, the BCQDB) with the original data
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latter can also be substituted by reliable external data if
it is the data0s accuracy and completeness that are being
assessed. Therefore, we measured the accuracy of the
BCQDB register by comparing all available risk, prog-
nostic, and predictive factors to distributions available
from external databases included in this study (see
above). These factors included patients0 age at breast-
cancer diagnosis, tumor location, tumor size (pT), node
status (pN), stage of the disease according to the Union
for International Cancer Control (UICC), grading, and
hormone-receptor status [19-21].
Measures of data completeness
To critically appraise the BCQDB register0s completeness,
established epidemiological measures were used [5,22-24].
We calculated raw age-specific incidence rates and cumu-
lative incidence curves in order to identify any possible
systematic deviations from external databases. We also
calculated direct age-standardized incidence rates for the
standard populations of both Europe and the world in
order to account for any possible age-related or demo-
graphic differences. In addition, we estimated indirect age-
standardized incidence rates, taking the population of the
German federal state of Saarland as the standard popula-
tion. This allowed the direct comparison between Saarland
and the administrative district of Marburg-Biedenkopf
without using neutral standard populations (e.g., Europe,
the world). This approach allowed us to account for the
demographic particularities of the Marburg-Biedenkopf
administrative district, which is the catchment area of the
BCQDB register. Finally, incidence-mortality ratios (IMR)
were calculated for each year to obtain further insights
into the BCQDB0s completeness [16,25,26].
Statistics
Rates and ratios were calculated for the BCQDB and then
compared to the corresponding figures for the various ex-
ternal databases. This statistical comparison was performed
using an exact binomial test with the specified “true” para-
meters of the selected secondary databases. The probability
of error of alpha was 0.05 [8,27]. The corresponding 95%
confidence intervals were derived using Pearson-Clopper
values which were based on F-distributions and which are
appropriate for small samples [7] characteristically sur-
veyed in rural areas (small-area analysis) [28]. Incidence-
based parameters and distributions of risk, prognostic, and
predictive factors were compared using overlapping 95%
confidence intervals based on Gaussian normal distribu-
tions [23,24].
Results
The survey recruited a total of N=877 patients (1996–97:
N=389, 2003–04: N=488) who were primarily treatedin the German administrative district of Marburg-
Biedenkopf. Of these incident patients N=577 (1996–97:
N=266, 2003–04: N=311) or 67% were registered as resi-
dents of that district and belonged to the epidemiologically
relevant sample. The comparison of epidemiological para-
meters and distributions with external databases was only
valid for residents. The BCQDB0s accuracy for the 1996–97
cohort is given in Table 1.
Comparison with the external data sources revealed
some isolated differences. These differences were ran-
domly distributed over the included parameters and did
not show any systematic patterns. Additional differences
were also detected for the 2003–04 cohort (see Table 2).
Table 2 indicates that the BCQDB register included
more women under the age of 49 years as well as fewer
patients in the 50–69 year range than the external data
sources. Our stratified analyses of women0s age at
breast-cancer diagnosis depending on the stage of the
disease suggest that older women were under-
represented in the BCQDB data. We checked this as-
sumption using the raw, age-specific, and cumulative in-
cidence curves. Figures 1, 2, 3, 4 show these results.
In the period from 1996–97, the age-specific incidence
rates (Figure 1) already began to show deviations at age
50 years. These tended to scatter arbitrarily around the
benchmark parameters. In the period from 2003–04,
similar deviations occurred from the age of 65 years
(Figure 2). Both BCQDB cohorts exhibited lower inci-
dence rates than in the epidemiological cancer register
of Saarland that begins approximately from the age of 75
years. The cumulative incidence rates (CIR), which
showed greater deviations for the 1996–97 cohort than
for the 2003–04 cohort (Figures 3, 4) conveyed a similar
impression. The “kinks” at age 55 years in the 1996–97
cohort and at age 65 years in the 2003–04 cohort were
especially revealing. The cumulative incidence rates were
CIR (BCQBD, 1996–97) = 10.0 and CIR (BCQBD,
2003–04) = 11.6 in comparison to CIR (SAAR, 1996–
97) = 11.9 and CIR (SAAR, 2003–04)= 12.5. However
these differences were not apparent in the directly age-
standardized incidence rates (SIR*, SIR**) or the indir-
ectly standardized incidence ratios (SIR***). Table 3
shows these results.
As expected, we found no systematic differences in
data completeness when using incidence rates that were
age-standardized. In contrast, our estimations using
incidence-mortality ratios (IMR) estimated completeness
to be low: IMR (1996–97) = 36.8 and IMR (2003–04) =
43.8. Detailed results on these incidence-mortality ratios
are given in Table 4.
Discussion
A wide and solid base of evidence is needed for rational
health policy decisions. New information technologies
Table 1 Accuracy of primary data (BCQDB) in comparison to external databases, period 1996-97
Secondary data Primary data 95% Confidence interval Test-statistic
Variable-level GER (θ1) BCQDB (θ2) Lower bound (θ2) Upper bound (θ2) p-value
00-49 years 21.4 24.4 19.4 30.1 ns
50-69 years 50.5 43.6 37.6 49.8 0.024
≥ 70 years 28.1 32.0 26.4 37.9 ns
pTis (non-invasive) 4.3 4.5 2.4 7.7 ns
pT1 (≤ 2cm) 47.4 53.0 46.8 59.1 ns
pT2 (≤ 5cm) 35.8 30.8 25.3 36.8 ns
pT3 (> 5cm) 4.7 2.6 1.1 5.3 ns
pT4 (involving other areals) 7.8 9.0 5.9 13.1 ns
pN+ 37.0 32.7 27.1 38.7 ns
Involved lymph nodes 0 60.9 63.4 57.0 69.6 ns
Involved lymph nodes 1-3 20.1 19.3 14.5 24.9 ns
Involved lymph nodes 4-9 11.8 10.5 6.9 15.1 ns
Involved lymph nodes >10 7.2 6.7 3.9 10.7 ns
Stage 0 4.2 4.5 2.4 7.7 ns
Stage 1 36.0 38.7 32.8 44.9 ns
Stage 2a 28.5 27.8 22.5 33.6 ns
Stage 2b 16.4 12.0 8.4 16.6 ns
Stage 3a 4.2 2.3 0.8 4.8 ns
Stage 3b 6.3 8.6 5.6 12.7 ns
Stage 4 4.5 6.0 3.5 9.6 ns
Grading 1 (G1) 11.3 7.9 4.9 11.9 ns
Grading 2 (G2) 55.8 43.3 37.1 49.6 <0.001
Grading 3 (G3) c32.9 48.8 42.5 55.1 <0.001
ERPR+ 82.0 83.5 78.4 87.7 ns
Variable-level GKR (θ1) BCQDB (θ2) Lower bound (θ2) Upper bound (θ2) p-value
00-49 years 20.4 24.4 19.4 30.1 ns
50-69 years 49.0 43.6 37.6 49.8 ns
≥ 70 years 30.6 32.0 26.4 37.9 ns
Left side 50.6 56.0 49.8 62.1 ns
Right side 47.7 44.0 37.9 50.2 ns
Breast quadrant I 48.6 46.6 40.5 52.8 ns
Breast quadrant II 12.3 11.3 7.7 15.7 ns
Breast quadrant III 9.1 11.7 8.1 16.1 ns
Breast quadrant IV 5.6 8.6 5.6 12.7 ns
Multifocal 16.6 17.3 12.9 22.4 ns
Mamille 7.8 4.5 2.4 7.7 0.045
Non-invasive tumor 5.8 4.5 2.4 7.7 ns
Stage 0 6.1 4.5 2.4 7.7 ns
Stage 1 38.4 38.7 32.8 44.9 ns
Stage 2 41.9 39.8 33.9 46.0 ns
Stage 3 8.0 10.9 7.4 15.3 ns
Stage 4 5.6 6.0 3.5 9.6 ns
Stage 0 | 0–49 years 7.0 7.7 2.5 17.0 ns
Jacke et al. BMC Research Notes 2012, 5:700 Page 4 of 12
http://www.biomedcentral.com/1756-0500/5/700
Table 1 Accuracy of primary data (BCQDB) in comparison to external databases, period 1996-97 (Continued)
Stage 1 | 0–49 years 38.0 36.9 25.3 49.8 ns
Stage 2 | 0–49 years 43.7 46.2 33.7 59.0 ns
Stage 3 | 0–49 years 6.5 6.2 1.7 15.0 ns
Stage 4 | 0–49 years 4.8 3.1 0.4 10.7 ns
Stage 0 | 50–69 years 6.9 4.3 1.4 9.8 ns
Stage 1 | 50–69 years 39.4 41.4 32.3 50.9 ns
Stage 2 | 50–69 years 41.0 42.2 33.1 51.8 ns
Stage 3 | 50–69 years 7.7 6.9 3.0 13.1 ns
Stage 4 | 50–69 years 5.0 5.2 1.9 10.9 ns
Stage 0 | ≥70 years 4.1 2.4 0.3 8.2 ns
Stage 1 | ≥70 years 36.9 36.5 26.3 47.6 ns
Stage 2 | ≥70 years 42.2 31.8 22.1 42.8 ns
Stage 3 | ≥70 years 9.7 20.0 12.1 30.1 <0.001
Stage 4 | ≥70 years 7.1 9.4 4.2 17.7 ns
(θ) Population parameter in percent, (GER) Mean of a five German regions for 1996–97 (Engel et al., 2002).
(BCQDB) Breast Cancer Query Database, Marburg, Germany; (GKR) Common Cancer Registers of the states.
Berlin, Brandenburg, Mecklenburg-Vorpommern, Saxony-Anhalt, Saxony and Thuringa (Stabenow & Eisinger, 2001).
(pN+) Pathological assessment of metastases in lymph nodes, (ERPR) Estrogen-Progesterone-Receptors.
(Multifocal) All quadrants involved, (Stage | age) Percent of patients with stage number conditional on age groups.
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mation relevant to health-policy decisions accessible. Tech-
nology may help increase the level of transparency in these
decisions. The breadth of evidence considered is especially
relevant for age-related diseases such as cancer because in-
cidence rates continue to rise in aging societies [29-31].
This growing trend is also apparent in the regional sample
of breast-cancer patients from the clinical register
(BCQDB) evaluated in this study. However, this rather
crude trend is not sufficient to justify calling the BCQDB
an epidemiologically relevant database. Therefore, its
accuracy and completeness was assessed.
Data accuracy
Comparison with external data sources of proven data
quality revealed that the BCQDB did not deviate sub-
stantially from these proven sources in terms of accur-
acy. In the period from 1996–97, 5 of 56 indicators
(8.9%) showed deviations, and in the years from 2003–
04, 8 of 53 indicators (15.1%) deviated systematically.
The increase in deviations between the two time periods
may be due to a selection bias. Therefore, the verifica-
tion of the register0s completeness was crucial.
Data completeness
The raw age-specific incidence curves we calculated
showed some fluctuations typical for surveys in rural
areas with small numbers of patients [28]. This is espe-
cially true for the higher age groups, which include fewer
patients as in this study. A more detailed inspection of
the cumulative-incidence curves (lifetime-prevalence)
also showed possible under-representations for patientsolder than 75 years (for 1996–97) and 65 years (for
2003–04). This could be interpreted as a sign of selec-
tion bias. However, some other details also make this in-
terpretation doubtful. First, the cumulative-incidence
curve for the 1996–97 cohort had a “kink” at age 55
years and then ran almost straight and parallel to the
comparator up to the higher age groups. This same
“kink” was also seen in the 2003–04 cohort, although
there it occurred at age 65 years instead of 55 years. This
phenomenon points to demographic shifts which are
particularly associated with age structure. Therefore, it
was necessary to standardize the raw incidence rates to
control for age effects.
Unstandardized and standardized measures
The direct age-standardized incidence rates offset the
BCQDB0s deviations from the external data sources that
were observed in the raw non-standardized indicators.
Particularly for the period from 2003–04, the age-
standardized incidence rates exhibited a strong conver-
gence to the reference parameters. This result was con-
firmed by indirect age-standardization methods, which
related raw age-specific incidence rates from the
BCQDB to the corresponding demographic population
parameters for Saarland. Therefore, it seems reasonable
to conclude that the regions0 differing age distributions
contributed substantially to the deviations observed in
the non-standardized rates. For this reason, estimates of
incidence-mortality ratios based on raw age-specific inci-
dence rates and official mortality figures cannot serve as
reliable indicators for the assessment of the BCQDB
register0s completeness.
Table 2 Accuracy of primary data (BCQDB) in comparison to external databases, period 2003-04
Secondard data Primary data 95% Confidence interval Test-statistic
Variable-level TRM (θ1) BCQDB ( θ2) Lower bound (θ2) Upper bound (θ2) p-value
00-49 years 18.9 22.4 17.9 27.5 ns
50-69 years 53.4 47.4 41.8 53.1 0.035
≥ 70 years 27.6 30.1 25.1 35.6 ns
Involved lymph nodes 0 61.1 68.4 62.7 73.8 0.011
Involved lymph nodes 1-3 23.0 20.0 15.5 25.1 ns
Involved lymph nodes 4-9 9.9 7.4 4.6 11.0 ns
Involved lymph nodes >10 6.0 4.2 2.2 7.2 ns
pTis (non-invasive) 7.0 6.7 4.2 10.1 ns
pT1 (≤ 2cm) 53.0 53.8 48.1 59.5 ns
pT2 (≤ 5cm) 31.4 31.1 26.0 36.5 ns
pT3 (> 5cm) 3.9 2.9 1.3 5.4 ns
pT4 (involving other areals) 4.7 5.4 3.2 8.6 ns
pTis | 0–49 years 7.0 7.1 2.4 15.9 ns
pT1 | 0–49 years 57.5 64.3 51.9 75.4 ns
pT2 | 0–49 years 29.9 27.1 17.2 39.1 ns
pT3 | 0–49 years 3.4 1.4 0.0 7.7 ns
pT4 | 0–49 years* 1.5 - - - -
pTis | 50–69 years 8.2 8.8 4.8 14.6 ns
pT1 | 50–69 years 57.2 56.1 47.7 64.2 ns
pT2 | 50–69 years 28.5 28.4 21.3 36.4 ns
pT3 | 50–69 years 3.3 3.4 1.1 7.7 ns
pT4 | 50–69 years 2.8 3.4 1.1 7.7 ns
pTis | ≥70 years 4.2 3.2 0.7 9.0 ns
pT1 | ≥70 years 41.9 42.6 32.4 53.2 ns
pT2 | ≥70 years 38.1 38.3 28.5 48.9 ns
pT3 | ≥70 years 5.4 4.3 1.2 10.5 ns
pT4 | ≥70 years 10.5 11.7 6.0 20.0 ns
Grading 1 (G1) 12.5 13.5 9.8 18.0 ns
Grading 2 (G2) 55.2 72.0 66.4 77.1 <0.001
Grading 3 (G3) 32.3 14.5 10.7 19.1 <0.001
Variable-level GKR (θ1) BCQDB ( θ2) Lower bound (θ2) Upper bound (θ2) p-value
00-49 years 20.6 22.4 17.9 27.5 ns
50-69 years 49.8 47.4 41.8 53.1 ns
≥ 70 years 29.6 30.1 25.1 35.6 ns
pTis (non-invasive) 7.8 6.7 4.2 10.1 ns
pT1 (≤ 2cm) 44.4 53.8 48.1 59.5 <0.001
pT2 (≤ 5cm) 36.7 31.1 26.0 36.5 0.04
pT3 (> 5cm) 4.9 2.9 1.3 5.4 ns
pT4 (involving other areals) 6.3 5.4 3.2 8.6 ns
pTis | 0–49 years 8.4 7.1 2.4 15.9 ns
pT1 | 0–49 years 46.8 64.3 51.9 75.4 0.003
pT2 | 0–49 years 36.4 27.1 17.2 39.1 ns
pT3 | 0–49 years 5.1 1.4 0.0 7.7 ns
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Table 2 Accuracy of primary data (BCQDB) in comparison to external databases, period 2003-04 (Continued)
pT4 | 0–49 years 3.2 - - - -
pTis | 50–69 years 9.0 8.8 4.8 14.6 ns
pT1 | 50–69 years 47.6 56.1 47.7 64.2 0.039
pT2 | 50–69 years 33.8 28.4 21.3 36.4 ns
pT3 | 50–69 years 4.5 3.4 1.1 7.7 ns
pT4 | 50–69 years 2.8 3.4 1.1 7.7 ns
pTis | ≥70 years 5.3 3.2 0.7 9.0 ns
pT1 | ≥70 years 37.3 42.6 32.4 53.2 ns
pT2 | ≥70 years 41.6 38.3 28.5 48.9 ns
pT3 | ≥70 years 5.5 4.3 1.2 10.5 ns
pT4 | ≥70 years 10.3 11.7 6.0 20.0 ns
(θ) Population parameter in percent, (TRM) Munich Tumor Register 11/2008 (Tumor Center Munich 2008), (BCQDB) Breast Cancer Query Register, Marburg,
Germany, (GKR) Common Cancer Registers of the states Berlin, Brandenburg, Mecklenburg-Vorpommern, Saxony-Anhalt, Saxony and Thuringa (GKR, 2008).
(Tumorsize | age) Percent of patients with tumorsize conditional on age groups, (−) No data.
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Based on the assessments of all calculated parameters
mentioned above, we conclude that the BCQDB register
contains sufficiently accurate, complete, and therefore
correct data. It seems safe to assume that the BCQDB
is of sufficient epidemiological relevance to allow for
further comparisons (e.g. adherence to clinical guide-
lines, analyses of survival, quality of life, and cost-
effectiveness). It can be used for further comparisons
and decisions.
Regional risk adjustments
These conclusions do not contradict the fact that the
variables of the data-quality indicator accuracy becameFigures 1 Raw age-specific incidence rates and cumulative incidence
Epidemiological Cancer Register for 1996–97 and 2003–04. Sub-figuremore divergent over time (increasing to 8 divergent indi-
cators out of 58 for the 2003–04 cohort). The systematic
deviations of certain surrogate parameters (e.g. fewer
nodal negatives, more small tumors under 2cm) indicate
that these increasing divergences may have been caused
by the health-care services themselves becoming more
effective in the intervening time interval. This interpret-
ation is supported by the increasing use of high quality
assured early-detection programs reported elsewhere
[32]. To actually measure the regional effects caused by
these early-detection programs, high utilization rates of
these programs among the target populations are crucial.
However, since the civil-register-based invitation sys-
tems, and thus their resulting utilization rates, varyrates from the breast cancer query database and the Saarland
(a): Raw incidence rates, 1996–97.
Figures 2 Raw age-specific incidence rates and cumulative incidence rates from the breast cancer query database and the Saarland
Epidemiological Cancer Register for 1996–97 and 2003–04. Sub-figure (b): Raw incidence rates, 2003–04.
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is methodologically impossible to make a fair and valid
comparison of the effectiveness of different regions0
health-care systems and corresponding registers. It is,
however, possible to compare different regions0 risk pro-
files, but any further conclusions regarding a region0s ef-
fectiveness would be biased [34]. Overcoming this
limitation would require additional data – collected at the
individual level and of sufficient quality. This would allow
valid comparisons, conclusions, and decisions to be made.Figures 3 Raw age-specific incidence rates and cumulative incidence
Epidemiological Cancer Register for 1996–97 and 2003–04. Sub-figureHarmonization of nomenclature and statistical definitions
Most countries, including Germany, have already taken
the first step toward comprehensive (cancer) registers
using and offering more epidemiological data by widely
implementing information technology in the health-care
field [35-37]. The next step is to assess and increase the
quality of data in a way that is guided by a theoretical
framework such as the GAMOQ. This approach would
help minimize doubts concerning the accuracy and com-
pleteness of databases. The regional differences displayedrates from the breast cancer query database and the Saarland
(c): Cumulative incidence rates, 1996–97.
Figures 4 Raw age-specific incidence rates and cumulative incidence rates from the breast cancer query database and the Saarland
Epidemiological Cancer Register for 1996–97 and 2003–04. Sub-figure (d): Cumulative incidence rates, 2003–04.
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in this study highlight how much room there is for inter-
pretation. In particular, harmonizing nomenclatures,
statistical distinctions, and reporting certain key para-
meters of registers or study characteristics could helpTable 3 Age-standardized incidence rates for Germany, Saarla
Germanya Saarlandb
95% Confidence level
Year SIR* SIR* Lower bound Upper bou
1996 98.2 103.1 95.3 110.9
1997 99.2 104.9 96.9 112.8
2003 102.3 114.3 106.2 122.5
2004 102.3 105.9 98.1 113.7
SIR** SIR** Lower bound Upper boun
1996 72.4 74.9 68.9 80.6
1997 73.1 76.9 70.9 82.9
2003 75.4 82.6 76.6 88.6





(a) Point estimates provided by German Center for Cancer Register Data 12/2010, (b
of Saarland, (c ) Point estimates and confidence intervals by Breast Cancer. Query D
(**) world standard population. (SIR***) Indirect age-standardized incidence ratio usinitiate this process [38], because problems stemming
from a data set0s definitional subtleties are difficult to
detect. To this end, a number of crucial indicators for
survival analysis reports (e.g. year of incidence, years of
follow-up etc.) have been proposed in addition to thend and Marburg-Biedenkopf
Marburg-Biedenkopfc
95% Confidence level















) Point estimates and confidence. Intervals by Epidemiological Cancer Register
atabase, (SIR) Direct age-standardized incidence ratio using (*) the european or
ing Saarland demographics as standard population.
Table 4 Mamma carcinoma incidence-mortality ratios for estimating completeness
Saarlanda Marburg-Biedenkopf
Incidence Mortality I:M Factor Mortalityb Expectedc Observedd Cumulative expected Cumulative observed
Ages 1996-97 1996-97 1996-97 1996-97 1996-97 1996-97 1996-97 1996-97
00 ≤ 25 0.5 0 - 0 - 0 - 0.0
25 ≤ 30 2.0 0 - 0 - 0 - 0.0
30 ≤ 35 11.0 0.5 22.0 2 44.0 2 44.0 2.0
35 ≤ 40 20.0 4.5 4.4 4 17.8 5 61.8 6.5
40 ≤ 45 49.0 10.5 4.7 4 18.7 8 80.4 14.5
45 ≤ 50 67.5 22.0 3.1 6 18.4 17 98.9 31.0
50 ≤ 55 62.0 14.5 4.3 10 42.8 8 141.6 39.0
55 ≤ 60 106.5 33.0 3.2 16 51.6 22 193.2 60.5
60 ≤ 65 89.0 30.5 2.9 6 17.5 16 210.8 76.0
65 ≤ 70 86.5 37.5 2.3 18 41.5 13 252.3 89.0
70 ≤ 75 105.0 30.5 3.4 12 41.3 25 293.6 113.5
75 ≤ 80 70.0 40.0 1.8 17 29.8 10 323.3 123.0
80 ≤ 85 54.0 29.5 1.8 14 25.6 4 349.0 127.0
85 and older 39.5 34.0 1.2 11 12.8 5 361.7 131.5
Period 2003-04 2003-04 2003-04 2003-04 2003-04 2003-04 2003-04 2003-04
0 ≤ 25 0.5 0 - 0 - 0 - 0.0
25 ≤ 30 1.0 0 - 1 - 0 - 0.0
30 ≤ 35 9.5 0.5 19.0 0 0.0 3 0 2.5
35 ≤ 40 18.5 6.5 2.8 3 8.5 10 8.5 12.0
40 ≤ 45 47.5 4.0 11.9 6 71.3 10 79.8 21.5
45 ≤ 50 64.5 10.5 6.1 4 24.6 12 104.4 33.5
50 ≤ 55 81.0 21.0 3.9 8 30.9 18 135.2 51.5
55 ≤ 60 84.5 22.5 3.8 7 26.3 16 161.5 67.0
60 ≤ 65 133.5 28.0 4.8 10 47.7 24 209.2 91.0
65 ≤ 70 111.5 27.0 4.1 9 37.2 17 246.4 107.5
70 ≤ 75 88.0 28.0 3.1 12 37.7 19 284.1 126.5
75 ≤ 80 87.5 33.5 2.6 11 28.7 11 312.8 137.5
80 ≤ 85 65.5 31.0 2.1 14 29.6 15 342.4 152.0
85 and older 44.5 32.0 1.4 10 13.9 3 356.3 154.5
(a) Epidemiological Cancer Register of Saarland 12/2010, (b) Regional statistic authorities of German federal state Hesse. (c) Age specific I:M factors multiplied by
mortality reported from regional statistic authorities, (d) Breast Cancer Query Database of Marburg-Biedenkopf district, (Incidence) Number of persons per age
group on average, (Mortality) Number of breast.cancer mortality per age group on average, (I:M) Incidence-Mortality; IM-Ratio(1996–97)= 131.5/361.7*100=36.4.
IM-Ratio(2003–94)=43.4, (−) No data.
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Overall, all these efforts attempt to facilitate valid com-
parisons and rational decisions.
Methodological strengths
The strength of this study was the approach that allowed
us to integrate the many different available data sources
and use them to estimate the epidemiological relevance
of the BCQDB. Doing so is especially advantageous for
small-scale population-based databases or for clinical
registers of rural areas. The reason we chose breastcancer as the exemplary disease with which to demon-
strate this procedure was because there are many pub-
licly available sources of breast-cancer data. However,
the procedure used in this study which is only one part
of the GAMOQs is also applicable to any other disease.
It goes beyond the usual comparison of epidemiological
measures and gives a deeper understanding of the rela-
tionship between a data set0s accuracy and completeness.
At this point it is worth emphasizing the analytic value
of non-standardized measures, which in this case
allowed regional differences and other irregularities to
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lysis. Such qualitative insights are of particular interest
before data has been analyzed and interpreted as they
can inform the analysis. In the case of the BCQDB, the
assessments of accuracy and completeness show that fu-
ture analyses should carefully conclude and interpret
data results particularly if patients are older than 65 or
75 years (depending on the cohort in question).
Methodological shortcomings
A general weakness of clinical registers working with
complete surveys that are administered only to utilizers of
regional breast cancer networks is the fact that selection
bias can occur [9]. Therefore, completeness-estimation
techniques such as the incidence-mortality ratios (IMR)
were developed to quantify to what extent the clinical
register did not capture missing cases. The IMR approach
belongs to the historical methods and a common thresh-
old of 90% or more has been established to consider a
register as complete [16,26]. However, in the context of a
small-area analysis using time-interval-bounded incidence
data as in this study, it is not possible to use incidence
mortality ratios (IMR) in the usual way to estimate the size
of target population not included in the data. This is be-
cause the already ill prevalent patients who died in the
observed time intervals (1996–97, 2003–04) were
excluded from the BCQDB-register by definition, and
were thus not captured in the mortality rates. These cases
are however counted in the official mortality statistics
taken from the official statistical authorities, and thus fig-
ure in to the “expected cases” factor in the denominator of
the IMRs. This leads to overestimated IMRs and thus to a
higher percentage of patients dying in a given time inter-
val. Therefore, our data-incompleteness estimates – which
estimated the number of cases missing from the data at
64% and 57% – were unrealistically high. Finally, the IMR
approach also entails all of the usual drawbacks associated
with disease-specific cause-of-death statistics and post-
mortem examinations [39,40].
Future potential of benchmarks
Further methodological developments for estimating the
correctness (e.g. accuracy, completeness) of data sets and
cohort studies will be necessary in the future, both in order
to allow researchers to gain access to the information that
remains hidden in the growing amount of data and to allow
this data to be exploited for epidemiologically and health-
economically valid comparisons, conclusions, and deci-
sions. There is demand for such new methodologies due to
infrastructural changes (such as integrated health-care net-
works, organ centers, and clinic chains) which are shifting
the focus to multidisciplinary oriented health care for
chronic diseases. Furthermore, these new organizational
developments are population-based and cover countries,states, districts, and counties. This means that demographic
distributions are available from statistical authorities, which
facilitates the estimation of incidence rates. Therefore, the
completeness estimation for a clinical register in question is
restricted to patients with permanent residence of the cor-
responding area and is not valid for non-resident patients
with the same disease. Under these circumstances, health-
care providers can be compared to external benchmarks.
This approach is superior to anonymous benchmarks based
on averages, because it allows much more than the usual
comparison of a few abstract quality indicators [41,42]. Spe-
cifically, it allows the best performers on a given quality in-
dicator to be used as the benchmark, enabling conclusions
to be drawn regarding how the benchmark organization
achieved its results as well as how similar results could be
achieved at the lower-performing organization. However to
attain such external quality assurance mechanisms, it is es-
sential to identify comparable organizations or institutions
which can be used as peer groups.
Conclusion
In this study, we proposed accuracy statistics that rely
on patients0 basic characteristics and common risk,
prognosis, and predictive factors. However, the list of
indicators could be more extensive to 1) describe the
general conditions of health care institutions and their
patients which were exposed to new performance-
enhancing quality tools (such as quality-management
systems) and 2) to compare and decide whether new
structural or process-related changes lead to expected
improvements. This approach helps to reproduce the
results gained in some (specialized) health care institu-
tions. It fosters the understanding why some innovations
have worked and others have not and how they are ap-
plicable to non-specialized institutions [43-45]. There-
fore, only the comparison between “equal” institutions
will allow for valid comparisons, conclusions, and sound
decisions that will lead to further improvements in the
quality and transparency of public health care.
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